Raul Gonzalez, MD
Internal Medicine · Rome, GANPI 1366503773
Payments from drug & device makers
Across 401 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Pfizer$930
- AbbVie$861
- Lilly USA, LLC$680
- Novo Nordisk$539
- Sanofi-aventis U.S. LLC$462
- plus $2K from 24 others
What the payments were for
- Consulting fees$2,60031%
- Food & beverage$5,85569%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $2,674 |
| Pfizer | 63 | $930 |
| AbbVie(2 entities) | 69 | $861 |
| Lilly USA, LLC | 54 | $680 |
| Novo Nordisk | 34 | $539 |
| Sanofi-aventis U.S. LLC | 24 | $462 |
| Boehringer Ingelheim | 25 | $404 |
| Amgen | 17 | $284 |
| AstraZeneca | 17 | $262 |
| Abbott | 13 | $207 |
| Amarin Pharma, Inc. | 11 | $144 |
| Johnson & Johnson | 10 | $139 |
| Astellas Pharma US Inc | 8 | $137 |
| Sumitomo Pharma America, Inc. | 9 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| Novartis | 6 | $83 |
| Mylan Specialty L.p. | 5 | $82 |
| Dexcom, Inc. | 2 | $77 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Merck | 3 | $35 |
| Exact Sciences | 1 | $21 |
| Gilead | 1 | $15 |
| Kaleo, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Roche Diabetes Care, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$8,490 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $205,758 |
| MounjaroTirzepatide | 161 | $190,736 |
| OzempicSemaglutide | 148 | $163,226 |
| JardianceEmpagliflozin | 88 | $97,520 |
| FarxigaDapagliflozin Propanediol | 88 | $94,699 |
| JanuviaSitagliptin Phosphate | 101 | $86,974 |
| RybelsusSemaglutide | 45 | $47,660 |
| XareltoRivaroxaban | 64 | $43,857 |
| LinzessLinaclotide | 67 | $38,274 |
| GemtesaVibegron | 45 | $32,476 |
| EntrestoSacubitril/Valsartan | 28 | $31,739 |
| TrulicityDulaglutide | 25 | $29,024 |
| MyrbetriqMirabegron | 55 | $25,951 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $24,734 |
| ProliaDenosumab | 11 | $18,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $680 | $219,760186 claims |
| Novo NordiskOzempic, Rybelsus | $539 | $210,886193 claims |
| PfizerEliquis, Premarin | $930 | $210,678182 claims |
| Boehringer IngelheimJardiance, Tradjenta | $404 | $109,625104 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $262 | $101,67999 claims |
| MerckJanuvia | $35 | $86,974101 claims |
| AbbVieLinzess, Synthroid, Namzaric | $861 | $51,878181 claims |
| Johnson & JohnsonXarelto | $139 | $43,85764 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $113 | $32,47645 claims |
| NovartisEntresto | $83 | $31,73928 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $25,95155 claims |
| GSKTrelegy Ellipta | $2,674 | $24,73421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Rome
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.